home / stock / biib / biib articles

BIIB Articles, Biogen Inc. - From 02/13/24

Stock Information
Company Name: Biogen Inc.
Stock Symbol: BIIB
Market: NASDAQ
Website: biogen.com
Menu
BIIB BIIB Quote BIIB Short BIIB News BIIB Articles BIIB Message Board
Get BIIB Alerts

News, Short Squeeze, Breakout and More Instantly...
Nasdaq, S&P 500 Set For Weaker Open As Traders Keep Eyes Peeled On Inflation Data: Analyst Flags Key CPI Report Item To Watch | Benzinga

Wall Street is poised to open in the red on Tuesday as stock futures declined ahead of the all-important consumer price inflation report for Janu...
Here's How Much You Would Have Made Owning Biogen Stock In The Last 20 Years | Benzinga

Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 1.7% on an annualized basis producing an average annual return of 9.28%....

Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines | Benzinga

Biogen Inc (NASDAQ:BIIB) is pulling the plug on its Aduhelm Alzheimer’s disease drug more than two years after the drug came into the limeli...

AT&T To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday | Benzinga

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts | Benzinga

UBS has downgraded Biogen Inc (NASDAQ:BIIB), noting inflection for its second Alzheimer’s drug Leqembi (lecanemab) will take l...

Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns | Benzinga

A new era in Alzheimer’s diagnosis is on the horizon as Dr. Suzanne Schindler and her team at Washington University School of Medic...

$1000 Invested In This Stock 20 Years Ago Would Be Worth $6,100 Today | Benzinga

Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 2.08% on an annualized basis producing an average annual return of 9.48%...
Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments | Benzinga

Wednesday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) released preliminary FY23 sales of $250 million-$260 million, compared to the consens...

Comparing Biogen With Industry Competitors In Biotechnology Industry | Benzinga

In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this artic...

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 | Benzinga

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
Previous 10 Next 10